Pancreatic Cancer Research

ResearcherMcGill University Health CentreActive in the last 2 years

Zu‐Hua Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7232-0933; OpenAlex author ID A5057948519. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: 1 paper

Papers 8

  1. The oncofetal protein IMP1 regulates the transcriptomic landscape to drive early events in pancreatic cancer progression and growth Co-author DOI 10.1101/2024.06.28.601273↗
  2. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. Co-author DOI 10.1136/jmedgenet-2021-108054↗
  3. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.860767↗
  4. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Co-author DOI 10.6004/jnccn.2021.7107↗
  5. Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale. Co-author DOI 10.6004/jnccn.2021.7049↗
  6. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  7. Serum level of co-expressed hub miRNAs as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. Last author DOI 10.7150/jca.27697↗
  8. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.12834↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George Zogopoulos · 6 shared papers, 2016–2022 · strength 0.62
  2. Yifan Wang · 5 shared papers, 2020–2022 · strength 0.57
  3. Bryn Golesworthy · 3 shared papers, 2022 · strength 0.36
  4. Sandra Elisabeth Fischer · 3 shared papers, 2020–2022 · strength 0.30
  5. Ayelet Borgida · 3 shared papers, 2020–2022 · strength 0.30
  6. Robert C. Grant · 3 shared papers, 2020–2022 · strength 0.30
  7. Grainne Mary O'Kane · 3 shared papers, 2020–2022 · strength 0.30
  8. Steve Gallinger · 3 shared papers, 2020–2022 · strength 0.30
  9. Orçun Haçarız · 1 shared paper, 2024 · strength 0.21
  10. Pnina Brodt · 1 shared paper, 2024 · strength 0.21
  11. Andrew M. Lowy · 1 shared paper, 2024 · strength 0.21
  12. Spring Holter · 2 shared papers, 2020–2022 · strength 0.19
  13. Jennifer Jane Knox · 2 shared papers, 2020–2022 · strength 0.19
  14. Jeffrey Stewart Barkun · 1 shared paper, 2022 · strength 0.14
  15. Yen‐I Chen · 1 shared paper, 2022 · strength 0.11
  16. Joan Miguel Romero · 1 shared paper, 2022 · strength 0.11
  17. Barbara T. Grünwald · 1 shared paper, 2022 · strength 0.11
  18. Qiang Su · 1 shared paper, 2018 · strength 0.09
  19. Talia Golan · 1 shared paper, 2020 · strength 0.07
  20. Chani Stossel · 1 shared paper, 2020 · strength 0.07
  21. Yasser Riazalhosseini · 1 shared paper, 2020 · strength 0.07
  22. Qing Li · 1 shared paper, 2016 · strength 0.05
  23. Hao Wang · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.